The average one-year price target for Spruce Biosciences (NasdaqCM:SPRB) has been revised to $235.11 / share. This is an increase of 10.02% from the prior estimate of $213.69 dated December 18, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $161.60 to a high of $297.15 / share. The average price target represents an increase of 188.48% from the latest reported closing price of $81.50 / share.
What is the Fund Sentiment?
There are 16 funds or institutions reporting positions in Spruce Biosciences. This is an increase of 5 owner(s) or 45.45% in the last quarter. Average portfolio weight of all funds dedicated to SPRB is 0.08%, an increase of 5,292.97%. Total shares owned by institutions increased in the last three months by 42.83% to 2,938K shares.
What are Other Shareholders Doing?
Carlyle Group holds 2,897K shares representing 270.61% ownership of the company.
Cable Car Capital holds 27K shares representing 2.49% ownership of the company.
Ikarian Capital holds 13K shares representing 1.25% ownership of the company.
Lion Point Capital holds 1K shares representing 0.09% ownership of the company.
Advisor Group Holdings holds 0K shares representing 0.01% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
